Page 4 - Pharmaceutical Firms

Alembic Pharma gets five observations from USFDA for Gujarat facility

Alembic Pharmaceuticals on Monday said the US health regulator has made five observations after inspection at its facility at Karkhadi, Gujarat. "The United States Food and Drug Administration (USFDA) has conducted an inspection at Alembic Pharmaceuticals' New Injectable Facility (F-3) located at Karkhadi from January 29-February 5, 2021. This was a scheduled inspection and at the end of the inspection, the USFDA issued a form 483 with 5 observations, the company said in a regulatory filing. As per the USFDA, a Form 483 is issued to a firm's management at the conclusion of an inspection when an investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. It notifies the company's management of objectionable conditions. Alembic Pharma said none of the observations were related to data integrity and were procedural in nature. "The company is preparing the response to the observations, which will be

Select pharma shares rally; Suven Pharma up 13%, Laurus nears record high

Healthcare companies to post decent growth in revenues in Q3FY21

Despite heroic work for Covid vaccine, pharma cos don't deserve affection

A financial analyst recently told that Pfizer's involvement in the coronavirus pandemic was about "as much public relations as it is a financial return

Aurobindo, Zydus, Jubilant, others recall various products in US market

Indian drug firms like Marksans Pharma, Aurobindo Pharma, Zydus and Jubilant are recalling products in the US market, as per the latest enforcement report by the USFDA

PLI scheme: Govt looks to get Rs 50,000 crore investments in pharma

The incentive will be in the range of 5-10 per cent of production value, sources said.

Divi's Lab, Aurobindo Pharma: Are pharma stocks losing their sheen? Read on

Till Nifty Pharma holds above the 11,180 mark, the bullish bias will prevail, charts suggest.

Pharma shares underperform in a firm market; Glenmark, Ipca Labs fall 6%

In the past month, the S&P BSE Healthcare index underperformed the market by falling 5 per cent, as compared to 5.4 per cent rise in the S&P BSE Sensex

Zydus Cadila Q2 net up four-fold on surge in US sales, strong show at home

Firm prunes net debt by 40% since March 2020; consolidated income up 13%

With 350% stock gain, drugmaker Laurus Labs seeks to boost capacity

The pharmaceutical sector is the top performer in India's $2.1 trillion equity market this year after the coronavirus pandemic turned global investors' spotlight on health-care companies

Glenmark Pharma launches pulmonary fibrosis treatment drug in India

Glenmark Pharma announced the launch of its generic version of Nintedanib (NINDANIB), used for the treatment of pulmonary fibrosis, in India

Pharma, FMCG push hiring activity in India by 24% in September: Naukri.com

Driven by industries like pharma, fast-moving consumer goods, education and IT, hiring activity in India saw a growth of 24% in September compared to the previous month

Madras HC orders formation of panel to ensure self-reliance in cancer drugs

In its judgment the court said India can not be dependent on China for APIs and ordered the formation of a five member committee to ensure self-reliance

Bank fraud case: 4 Sterling directors declared fugitive economic offenders

A Delhi court on Monday declared four directors of a Gujarat-based pharma firm,Sterling Biotech Ltd (SBL), fugitive economic offenders in a Rs 8,100-crore bank fraud case

Hetero launches pack of generic Covid-19 drug favipiravir at Rs 2,640

Drug firm Hetero on Friday said it has launched a pack of its generic oral antiviral drug-- Favivir 800/200-- for the treatment of mild-to-moderate symptomatic COVID-19 patients in India.

Higher exports to help pharma eke out 8-9% growth this fiscal: CRISIL

Living up to its moniker of a defensive bet, the Rs 2.8 trn Indian pharmaceutical sector is set to emerge more or less unscathed from the Covid-19 pandemic this fiscal, CRISIL said on Thursday.

India probing alleged dumping of chemical from China, South Korea

In the probe, the directorate will determine the existence, degree and effect of any alleged dumping in respect of the product from China

Pharma companies committed to science-first policy on Covid-19 vaccine

Pharmaceutical companies are committed to a science first approach in the development of COVID-19 vaccines even as the pressure piles on to end the pandemic

Zydus Cadila gets USFDA nod to market mineral supplement tablets

Zydus Cadila said it has received approval from USFDA to market potassium chloride extended release tablets, a mineral supplement used to treat or prevent low amounts of potassium in the blood

Dr Reddy's, Biocon, Torrent Pharma: What charts indicate for these stocks

The next upside for Nifty Pharma is located above the resistance of 12,100 levels.

Gilead to buy cancer drugmaker Immunomedics Inc for $21 billion

Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug